Combination Therapy of Clinically Approved Antifungal Drugs Is Enhanced by Conjugation with Silver Nanoparticles

Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56(12):1724–1732

Anwar A, Siddiqui R, Hussain MA, Ahmed D, Shah MR, Khan NA (2018) Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole. Parasitol Res 117(1):265–271

Araiza J, Canseco P, Bonifaz A (2006) Otomycosis: clinical and mycological study of 97 cases. Rev Laryngol Otol Rhinol 127(4):251–254

Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B (2013) Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 19(8):E343–E353

Atta-ur-Rahman SA, Abbas FN, Ahmed G, Choudhary MI, Alvi KA, De Silva KTD, Arambewela LSR (1991) Chemical constituents of Alstonia macrophylla. J Nat Prod 54:750–754

Carlson C, Hussain SM, Schrand AMK, Braydich-Stolle L, Hess KL, Jones RL, Schlager JJ (2008) Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B 112(43):13608–13619

Espinel-Ingroff A, Shadomy S (1989) In vitro and in vivo evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis 8(4):352–361

Fianchi L, Picardi M, Cudillo L, Corvatta L, Mele L, Trape G, Girmenia C, Pagano L (2004) Aspergillus niger infection in patients with haematological diseases: a report of eight cases. Mycoses 47:163–167

Hayden NJ, Maude RB, Proctor FJ (1994) Studies on the biology of black mould (Aspergillus niger) on temperate and tropical onions. 1. A comparison of sources of the disease in temperate and tropical field crops. Plant Pathol 43(3):562–569

Hoppe JE, Hahn H, Antimycotics Study Group (1996) Randomized comparison of two nystatin oral gels with miconazole oral gel for treatment of oral thrush in infants. Infection 24(2):136–139

Huh AJ, Kwon YJ (2011) “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 156(2):128–145

Hussein-Al-Ali SH, El Zowalaty ME, Kura AU, Geilich B, Fakurazi S, Webster TJ, Hussein MZ (2014) Antimicrobial and controlled release studies of a novel nystatin conjugated iron oxide nanocomposite. Biomed Res Int 2014:651831

Khan NA, Siddiqui R (2009) Acanthamoeba affects the integrity of human brain microvascular endothelial cells and degrades the tight junction proteins. Int J Parasitol 39(14):1611–1616

Kim KJ, Sung WS, Moon SK, Choi JS, Kim JG, Lee DG (2008) Antifungal effect of silver nanoparticles on dermatophytes. J Microbiol Biotechnol 18(8):1482–1484

Kumar CG, Poornachandra Y (2015) Biodirected synthesis of Miconazole-conjugated bacterial silver nanoparticles and their application as antifungal agents and drug delivery vehicles. Colloids Surf B: Biointerfaces 125:110–119

Loudon KW, Coke AP, Burnie JP, Shaw AJ, Oppenheim BA, Morris CQ (1996) Kitchens as a source of Aspergillus niger infection. J Hosp Infect 32(3):191–198

Lumbreras C, Cuervas-Mons V, Jara P, Del Palacio A, Turrion VS, Barrios C, Moreno E, Noriega AR, Paya CV (1996) Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174(3):583–588

Malhotra S, Singh S, Rana N, Tomar S, Bhatnagar P, Gupta M, Singh SK, Singh BK, Chhillar AK, Prasad AK, Len C (2017) Chemoenzymatic synthesis, nanotization and anti-Aspergillus activity of optically enriched fluconazole analogues. Antimicrob Agents Chemother 61:e00273–17.

Moazeni M, Kelidari HR, Saeedi M, Morteza-Semnani K, Nabili M, Gohar AA, Akbari J, Lotfali E, Nokhodchi A (2016) Time to overcome fluconazole resistant Candida isolates: solid lipid nanoparticles as a novel antifungal drug delivery system. Colloids Surf B: Biointerfaces 142:400–407

Mohammadi G, Shakeri A, Fattahi A, Mohammadi P, Mikaeili A, Aliabadi A, Adibkia K (2017) Preparation, physicochemical characterization and anti-fungal evaluation of nystatin-loaded PLGA-glucosamine nanoparticles. Pharm Res 34:301–309

Monteiro DR, Gorup LF, Silva S, Negri M, De Camargo ER, Oliveira R, Barbosa DD, Henriques M (2011) Silver colloidal nanoparticles: antifungal effect against Candida albicans and Candida glabrata adhered cells and biofilms. Biofouling 27(7):711–719

Monteiro DR, Silva S, Negri M, Gorup LF, De Camargo ER, Oliveira R, Barbosa DD, Henriques M (2012) Silver nanoparticles: influence of stabilizing agent and diameter on antifungal activity against Candida albicans and Candida glabrata biofilms. Lett Appl Microbiol 54(5):383–391

Monteiro DR, Silva S, Negri M, Gorup LF, De Camargo ER, Oliveira R, Barbosa DB, Henriques M (2013) Antifungal activity of silver nanoparticles in combination with nystatin and chlorhexidine digluconate against Candida albicans and Candida glabrata biofilms. Mycoses 56(6):672–680

Naglik JR, Moyes DL, Wächtler B, Hube B (2011) Candida albicans interactions with epithelial cells and mucosal immunity. Clin Microbiol Infect 13(12–13):963–976

Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, Kryštof V, Hamal P, Zbořil R, Kvítek L (2009) Antifungal activity of silver nanoparticles against Candida spp. Biomaterials 30(31):6333–6340

Patterson TF (2007) Treatment and prevention of fungal infections. Focus on candidemia. Appl Clin Edu, New York, pp VII–VIII

Person AK, Chudgar SM, Norton BL, Tong BC, Stout JE (2010) Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol 59(7):834–838

Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133–163

Pfaller MA, Pappas PG, Wingard JR (2006) Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 43(Supplement_1):S3–S14

Prabhu S, Poulose EK (2012) Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int Nano Lett 2(1):32

Rai M, Yadav A, Gade A (2009) Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 27(1):76–83

Rajendran K, Anwar A, Khan NA, Siddiqui R (2017) Brain-eating amoebae: Silver nanoparticle conjugation enhanced efficacy of anti-amoebic drugs against Naegleria fowleri. ACS Chem Neurosci 8(12):2626–2630

Roemer T, Krysan DJ (2014) Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 4(5):A019703

Sarrafha MR, Hashemi SJ, Rezaei S, Bayat M (2018) In vitro evaluation of the effects of fluconazole and nano-fluconazole on Aspergillus flavus and Aspergillus fumigatus isolates. Jundishapur J Microbiol 11(6):e57875

Silva S, Pires P, Monteiro DR, Negri M, Gorup LF, Camargo ER, Barbosa DB, Oliveira R, Williams DW, Henriques M, Azeredo J (2013) The effect of silver nanoparticles and nystatin on mixed biofilms of Candida glabrata and Candida albicans on acrylic. Med Mycol 51(2):178–184

Sondi I, Salopek-Sondi B (2004) Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interfac Sci 275(1):177–182

Vermeulen E, Maertens J, Meersseman P, Saegeman V, Dupont L, Lagrou K (2014) Invasive Aspergillus niger complex infections in a Belgian tertiary care hospital. Clin Microbiol Infect 20(5):O333–O335

Zhang L, Pornpattananangkul D, Hu CM, Huang CM (2010) Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 17(6):585–594